{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:18:10Z","timestamp":1788391090261,"version":"build-2803163510"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins &amp; Other Lipid Mediators"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.prostaglandins.2020.106484","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T03:02:16Z","timestamp":1601434936000},"page":"106484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Sphingolipid metabolism as a marker of hepatotoxicity in drug-induced liver injury"],"prefix":"10.1016","volume":"151","author":[{"given":"Linhao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jace W.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.prostaglandins.2020.106484_bib0005","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nrd3025","article-title":"The future of drug development: advancing clinical trial design","volume":"8","author":"Orloff","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.prostaglandins.2020.106484_bib0010","first-page":"73","article-title":"Drug-induced liver injury","volume":"6","author":"David","year":"2010","journal-title":"US Gastroenterol. Hepatol. Rev."},{"issue":"2","key":"10.1016\/j.prostaglandins.2020.106484_bib0015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-2002-30105","article-title":"Epidemiology and individual susceptibility to adverse drug reactions affecting the liver","volume":"22","author":"Larrey","year":"2002","journal-title":"Semin. Liver Dis."},{"issue":"6","key":"10.1016\/j.prostaglandins.2020.106484_bib0020","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1002\/hep.23937","article-title":"Drug-induced acute liver failure: results of a U.S. multicenter, prospective study","volume":"52","author":"Reuben","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.prostaglandins.2020.106484_bib0025","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/hec.1454","article-title":"Spending on new drug development1","volume":"19","author":"Adams","year":"2010","journal-title":"Health Econ."},{"issue":"2","key":"10.1016\/j.prostaglandins.2020.106484_bib0030","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1377\/hlthaff.25.2.420","article-title":"Estimating the cost of new drug development: is it really 802 million dollars?","volume":"25","author":"Adams","year":"2006","journal-title":"Health Aff. (Millwood)"},{"issue":"2","key":"10.1016\/j.prostaglandins.2020.106484_bib0035","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0167-6296(02)00126-1","article-title":"The price of innovation: new estimates of drug development costs","volume":"22","author":"DiMasi","year":"2003","journal-title":"J. Health Econ."},{"issue":"8","key":"10.1016\/j.prostaglandins.2020.106484_bib0040","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nrd1470","article-title":"Can the pharmaceutical industry reduce attrition rates?","volume":"3","author":"Kola","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.prostaglandins.2020.106484_bib0045","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1053\/j.gastro.2011.09.051","article-title":"Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury","volume":"142","author":"Moustafa","year":"2012","journal-title":"Gastroenterology."},{"issue":"1","key":"10.1016\/j.prostaglandins.2020.106484_bib0050","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12944-018-0683-y","article-title":"Serum lipids as an indicator for the alteration of liver function in patients with hepatitis B","volume":"17","author":"Arain","year":"2018","journal-title":"Lipids Health Dis."},{"issue":"1","key":"10.1016\/j.prostaglandins.2020.106484_bib0055","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.yexmp.2014.05.002","article-title":"Lipidomic analysis of the liver from high-fat diet induced obese mice identifies changes in multiple lipid classes","volume":"97","author":"Eisinger","year":"2014","journal-title":"Exp. Mol. Pathol."},{"issue":"18","key":"10.1016\/j.prostaglandins.2020.106484_bib0060","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1038\/sj.emboj.7600798","article-title":"Cellular lipidomics","volume":"24","author":"van Meer","year":"2005","journal-title":"EMBO J."},{"issue":"8","key":"10.1016\/j.prostaglandins.2020.106484_bib0065","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/nrm2934","article-title":"Lipidomics: coming to grips with lipid diversity","volume":"11","author":"Shevchenko","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.prostaglandins.2020.106484_bib0070","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.cell.2010.11.033","article-title":"Lipidomics: new tools and applications","volume":"143","author":"Wenk","year":"2010","journal-title":"Cell."},{"key":"10.1016\/j.prostaglandins.2020.106484_bib0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4419-6741-1_1","article-title":"An overview of sphingolipid metabolism: from synthesis to breakdown","volume":"688","author":"Gault","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"issue":"10","key":"10.1016\/j.prostaglandins.2020.106484_bib0080","doi-asserted-by":"crossref","first-page":"6387","DOI":"10.1021\/cr2002917","article-title":"Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics","volume":"111","author":"Merrill","year":"2011","journal-title":"Chem. Rev."},{"issue":"17","key":"10.1016\/j.prostaglandins.2020.106484_bib0085","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1007\/s00018-007-7076-0","article-title":"The metabolism and function of sphingolipids and glycosphingolipids","volume":"64","author":"Lahiri","year":"2007","journal-title":"Cell. Molecul. Life Sci. CMLS."},{"key":"10.1016\/j.prostaglandins.2020.106484_bib0090","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s40495-017-0093-2","article-title":"Sphingosine Kinases\/Sphingosine 1-Phosphate signaling in hepatic lipid metabolism","volume":"3","author":"Kwong","year":"2017","journal-title":"Curr. Pharmacol. Rep."},{"issue":"6\u20137","key":"10.1016\/j.prostaglandins.2020.106484_bib0095","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1515\/hsz-2014-0296","article-title":"Sphingolipids in liver injury, repair and regeneration","volume":"396","author":"Nojima","year":"2015","journal-title":"Biol. Chem."},{"issue":"43","key":"10.1016\/j.prostaglandins.2020.106484_bib0100","doi-asserted-by":"crossref","first-page":"30904","DOI":"10.1074\/jbc.M112.448852","article-title":"Protection of a ceramide synthase 2 null mouse from drug-induced liver injury: role of gap junction dysfunction and connexin 32 mislocalization","volume":"288","author":"Park","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.prostaglandins.2020.106484_bib0105","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1478-3231.2007.01475.x","article-title":"Sphingolipid signalling and liver diseases","volume":"27","author":"Mari","year":"2007","journal-title":"Liver Int."},{"issue":"4","key":"10.1016\/j.prostaglandins.2020.106484_bib0110","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1172\/JCI59755","article-title":"The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation","volume":"122","author":"McGill","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.prostaglandins.2020.106484_bib0115","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.cld.2013.07.002","article-title":"Mechanisms of drug-induced liver injury","volume":"17","author":"Yuan","year":"2013","journal-title":"Clin. Liver Dis."},{"issue":"4","key":"10.1016\/j.prostaglandins.2020.106484_bib0120","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1472-8206.2008.00608.x","article-title":"Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies","volume":"22","author":"Labbe","year":"2008","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"32","key":"10.1016\/j.prostaglandins.2020.106484_bib0125","doi-asserted-by":"crossref","first-page":"27855","DOI":"10.1074\/jbc.R111.254359","article-title":"Many ceramides","volume":"286","author":"Hannun","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.prostaglandins.2020.106484_bib0130","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/hepr.12352","article-title":"Inhibition of acidic sphingomyelinase reduces established hepatic fibrosis in mice","volume":"45","author":"Quillin","year":"2015","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.prostaglandins.2020.106484_bib0135","doi-asserted-by":"crossref","first-page":"e929","DOI":"10.1038\/cddis.2013.451","article-title":"Altering the sphingolipid acyl chain composition prevents LPS\/GLN-mediated hepatic failure in mice by disrupting TNFR1 internalization","volume":"4","author":"Ali","year":"2013","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.prostaglandins.2020.106484_bib0140","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1172\/JCI16010","article-title":"Defective TNF-alpha-mediated hepatocellular apoptosis and liver damage in acidic sphingomyelinase knockout mice","volume":"111","author":"Garcia-Ruiz","year":"2003","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.prostaglandins.2020.106484_bib0145","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1124\/mol.108.046656","article-title":"The peripheral benzodiazepine receptor ligand 1-(2-chlorophenyl-methylpropyl)-3-isoquinoline-carboxamide is a novel antagonist of human constitutive androstane receptor","volume":"74","author":"Li","year":"2008","journal-title":"Mol. Pharmacol."},{"issue":"22","key":"10.1016\/j.prostaglandins.2020.106484_bib0150","doi-asserted-by":"crossref","first-page":"12480","DOI":"10.1021\/acs.analchem.7b03576","article-title":"A comprehensive high-resolution targeted workflow for the deep profiling of sphingolipids","volume":"89","author":"Peng","year":"2017","journal-title":"Anal. Chem."},{"issue":"8","key":"10.1016\/j.prostaglandins.2020.106484_bib0155","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1194\/jlr.D047795","article-title":"Enhanced lipid isomer separation in human plasma using reversed-phase UPLC with ion-mobility\/high-resolution MS detection","volume":"55","author":"Damen","year":"2014","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.prostaglandins.2020.106484_bib0160","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1021\/ac503715v","article-title":"Ion mobility-derived collision cross section as an additional measure for lipid fingerprinting and identification","volume":"87","author":"Paglia","year":"2015","journal-title":"Anal. Chem."},{"issue":"1","key":"10.1016\/j.prostaglandins.2020.106484_bib0165","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1002\/cpbi.86","article-title":"Using MetaboAnalyst 4.0 for comprehensive and integrative metabolomics data analysis","volume":"68","author":"Chong","year":"2019","journal-title":"Curr. Protoc. Bioinformatics"},{"key":"10.1016\/j.prostaglandins.2020.106484_bib0170","doi-asserted-by":"crossref","DOI":"10.1002\/0471250953.bi1410s34","article-title":"Metabolomic data processing, analysis, and interpretation using MetaboAnalyst","author":"Xia","year":"2011","journal-title":"Curr. Protoc. Bioinformatics"},{"issue":"12","key":"10.1016\/j.prostaglandins.2020.106484_bib0175","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.1021\/ac5009964","article-title":"Improved sphingolipidomic approach based on ultra-high performance liquid chromatography and multiple mass spectrometries with application to cellular neurotoxicity","volume":"86","author":"Wang","year":"2014","journal-title":"Anal. Chem."},{"key":"10.1016\/j.prostaglandins.2020.106484_bib0180","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0076-6879(07)32004-1","article-title":"Structure-specific, quantitative methods for analysis of sphingolipids by liquid chromatography-tandem mass spectrometry: \u201cinside-out\u201d sphingolipidomics","volume":"432","author":"Sullards","year":"2007","journal-title":"Meth. Enzymol."},{"issue":"31","key":"10.1016\/j.prostaglandins.2020.106484_bib0185","doi-asserted-by":"crossref","first-page":"5146","DOI":"10.1016\/j.chroma.2011.05.081","article-title":"Lipidomic profiling of biological tissues using off-line two-dimensional high-performance liquid chromatography-mass spectrometry","volume":"1218","author":"Lisa","year":"2011","journal-title":"J. Chromatogr. A"},{"issue":"3","key":"10.1016\/j.prostaglandins.2020.106484_bib0190","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.3822","article-title":"Ultraperformance convergence chromatography-high resolution tandem mass spectrometry for lipid biomarker profiling and identification","volume":"31","author":"Jones","year":"2017","journal-title":"Biomedical chromatography: BMC."},{"issue":"4","key":"10.1016\/j.prostaglandins.2020.106484_bib0195","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1039\/C8SC04396E","article-title":"Collision cross section compendium to annotate and predict multi-omic compound identities","volume":"10","author":"Picache","year":"2019","journal-title":"Chem. Sci."},{"issue":"12","key":"10.1016\/j.prostaglandins.2020.106484_bib0200","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.bbalip.2018.09.002","article-title":"Widespread tissue distribution and synthetic pathway of polyunsaturated C24:2 sphingolipids in mammals","volume":"1863","author":"Edagawa","year":"2018","journal-title":"Biochimica et biophysica acta Molecular and cell biology of lipids."},{"key":"10.1016\/j.prostaglandins.2020.106484_bib0205","doi-asserted-by":"crossref","DOI":"10.1096\/fj.201902645R","article-title":"Biosynthesis of the anti-lipid-microdomain sphingoid base 4,14-sphingadiene by the ceramide desaturase FADS3","author":"Jojima","year":"2020","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.prostaglandins.2020.106484_bib0210","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.taap.2014.05.010","article-title":"Mechanisms of acetaminophen-induced cell death in primary human hepatocytes","volume":"279","author":"Xie","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"4","key":"10.1016\/j.prostaglandins.2020.106484_bib0215","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.tiv.2008.02.001","article-title":"Interspecies differences in acetaminophen sensitivity of human, rat, and mouse primary hepatocytes","volume":"22","author":"Jemnitz","year":"2008","journal-title":"Toxicol. Vitro."},{"issue":"11","key":"10.1016\/j.prostaglandins.2020.106484_bib0220","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1517\/17425255.2014.967680","article-title":"Competency of different cell models to predict human hepatotoxic drugs","volume":"10","author":"Gomez-Lechon","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"3","key":"10.1016\/j.prostaglandins.2020.106484_bib0225","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.cld.2007.06.006","article-title":"Acetaminophen hepatotoxicity","volume":"11","author":"Larson","year":"2007","journal-title":"Clin. Liver Dis."},{"issue":"7173","key":"10.1016\/j.prostaglandins.2020.106484_bib0230","first-page":"1609","article-title":"Proudfoot A. Paracetamol (acetaminophen) poisoning. No need to change current guidelines to accident departments","volume":"317","author":"Routledge","year":"1998","journal-title":"BMJ"},{"issue":"30","key":"10.1016\/j.prostaglandins.2020.106484_bib0235","doi-asserted-by":"crossref","first-page":"27879","DOI":"10.1074\/jbc.M503002200","article-title":"Roles for C16-ceramide and sphingosine 1-phosphate in regulating hepatocyte apoptosis in response to tumor necrosis factor-alpha","volume":"280","author":"Osawa","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"14","key":"10.1016\/j.prostaglandins.2020.106484_bib0240","doi-asserted-by":"crossref","first-page":"10911","DOI":"10.1074\/jbc.M109.077610","article-title":"A critical role for ceramide synthase 2 in liver homeostasis: II. Insights into molecular changes leading to hepatopathy","volume":"285","author":"Pewzner-Jung","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"14","key":"10.1016\/j.prostaglandins.2020.106484_bib0245","doi-asserted-by":"crossref","first-page":"10902","DOI":"10.1074\/jbc.M109.077594","article-title":"A critical role for ceramide synthase 2 in liver homeostasis: I. Alterations in lipid metabolic pathways","volume":"285","author":"Pewzner-Jung","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.prostaglandins.2020.106484_bib0250","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1194\/jlr.D300025-JLR200","article-title":"Quantification of sphingosine and sphinganine from crude lipid extracts by HPLC electrospray ionization tandem mass spectrometry","volume":"44","author":"Lieser","year":"2003","journal-title":"J. Lipid Res."},{"issue":"8","key":"10.1016\/j.prostaglandins.2020.106484_bib0255","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1194\/jlr.D600012-JLR200","article-title":"Characterization and direct quantitation of sphingoid base-1-phosphates from lipid extracts: a shotgun lipidomics approach","volume":"47","author":"Jiang","year":"2006","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.prostaglandins.2020.106484_bib0260","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ymeth.2005.01.009","article-title":"Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry","volume":"36","author":"Merrill","year":"2005","journal-title":"Methods"},{"issue":"8","key":"10.1016\/j.prostaglandins.2020.106484_bib0265","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0022-2275(20)33398-8","article-title":"Quantitative measurement of different ceramide species from crude cellular extracts by electrospray ionization tandem mass spectrometry (ESI-MS\/MS)","volume":"40","author":"Liebisch","year":"1999","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.prostaglandins.2020.106484_bib0270","first-page":"39","article-title":"A review of lipidomic technologies applicable to sphingolipidomics and their relevant applications","volume":"111","author":"Han","year":"2009","journal-title":"EJLST."},{"issue":"8","key":"10.1016\/j.prostaglandins.2020.106484_bib0275","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1194\/jlr.D800051-JLR200","article-title":"Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers","volume":"50","author":"Shaner","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.prostaglandins.2020.106484_bib0280","doi-asserted-by":"crossref","DOI":"10.1194\/jlr.M094722","article-title":"Probing compartment-specific sphingolipids with targeted bacterial sphingomyelinases and ceramidases","author":"Sakamoto","year":"2019","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.prostaglandins.2020.106484_bib0285","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.molcel.2010.10.005","article-title":"Membranes in balance: mechanisms of sphingolipid homeostasis","volume":"40","author":"Breslow","year":"2010","journal-title":"Mol. Cell"},{"issue":"2\u20133","key":"10.1016\/j.prostaglandins.2020.106484_bib0290","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s12035-009-8096-6","article-title":"Deregulated sphingolipid metabolism and membrane organization in neurodegenerative disorders","volume":"41","author":"Piccinini","year":"2010","journal-title":"Mol. Neurobiol."},{"issue":"3","key":"10.1016\/j.prostaglandins.2020.106484_bib0295","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.neurobiolaging.2008.05.010","article-title":"Deregulation of sphingolipid metabolism in Alzheimer\u2019s disease","volume":"31","author":"He","year":"2010","journal-title":"Neurobiol. Aging"},{"issue":"11","key":"10.1016\/j.prostaglandins.2020.106484_bib0300","doi-asserted-by":"crossref","first-page":"10284","DOI":"10.1074\/jbc.M412348200","article-title":"Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice","volume":"280","author":"Hojjati","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.prostaglandins.2020.106484_bib0305","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4330\/wjc.v5.i4.75","article-title":"Sphingolipids in cardiovascular and cerebrovascular systems: pathological implications and potential therapeutic targets","volume":"5","author":"Kawabori","year":"2013","journal-title":"World J. Cardiol."},{"issue":"20","key":"10.1016\/j.prostaglandins.2020.106484_bib0310","doi-asserted-by":"crossref","first-page":"13538","DOI":"10.1074\/jbc.M709950200","article-title":"Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1","volume":"283","author":"Shah","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.prostaglandins.2020.106484_bib0315","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.2337\/db09-1293","article-title":"Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption","volume":"59","author":"Ussher","year":"2010","journal-title":"Diabetes."},{"key":"10.1016\/j.prostaglandins.2020.106484_bib0320","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.critrevonc.2019.03.018","article-title":"Sphingolipids and acid ceramidase as therapeutic targets in cancer therapy","volume":"138","author":"Govindarajah","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.prostaglandins.2020.106484_bib0325","doi-asserted-by":"crossref","first-page":"565316","DOI":"10.1155\/2011\/565316","article-title":"Apoptotic sphingolipid ceramide in cancer therapy","volume":"2011","author":"Huang","year":"2011","journal-title":"J. Lipids"},{"issue":"2","key":"10.1016\/j.prostaglandins.2020.106484_bib0330","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4161\/cbt.11.2.14624","article-title":"Dysregulation of sphingolipid metabolism in cancer","volume":"11","author":"Ryland","year":"2011","journal-title":"Cancer Biol. Ther."},{"issue":"10","key":"10.1016\/j.prostaglandins.2020.106484_bib0335","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.tcb.2006.08.009","article-title":"Biophysical properties of lipids and dynamic membranes","volume":"16","author":"Janmey","year":"2006","journal-title":"Trends Cell Biol."},{"issue":"5","key":"10.1016\/j.prostaglandins.2020.106484_bib0340","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/embor.2010.60","article-title":"Membranes in motion","volume":"11","author":"van Meer","year":"2010","journal-title":"EMBO Rep."},{"issue":"9","key":"10.1016\/j.prostaglandins.2020.106484_bib0345","doi-asserted-by":"crossref","first-page":"5677","DOI":"10.1074\/jbc.M707386200","article-title":"Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate","volume":"283","author":"Laviad","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.prostaglandins.2020.106484_bib0350","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1139\/o03-091","article-title":"Acid and neutral sphingomyelinases: roles and mechanisms of regulation","volume":"82","author":"Marchesini","year":"2004","journal-title":"Biochem. Cell Biol."},{"issue":"1","key":"10.1016\/j.prostaglandins.2020.106484_bib0355","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000315101","article-title":"Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications","volume":"26","author":"Kornhuber","year":"2010","journal-title":"Cell. Physiol. Biochem."},{"issue":"3","key":"10.1016\/j.prostaglandins.2020.106484_bib0360","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.bbamcr.2005.09.001","article-title":"Ceramide-enriched membrane domains","volume":"1746","author":"Bollinger","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.prostaglandins.2020.106484_bib0365","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2174\/1874312901206010123","article-title":"Sphingolipid regulation of tissue fibrosis","volume":"6","author":"Shea","year":"2012","journal-title":"Open Rheumatol. J."},{"issue":"2","key":"10.1016\/j.prostaglandins.2020.106484_bib0370","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrm2329","article-title":"Principles of bioactive lipid signalling: lessons from sphingolipids","volume":"9","author":"Hannun","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.prostaglandins.2020.106484_bib0375","first-page":"25","article-title":"Biological effects of lysophospholipids. Reviews of physiology","volume":"160","author":"Rivera","year":"2008","journal-title":"biochemistry and pharmacology."}],"container-title":["Prostaglandins &amp; Other Lipid Mediators"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882320300770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098882320300770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:01:43Z","timestamp":1761098503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098882320300770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":75,"alternative-id":["S1098882320300770"],"URL":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2020.106484","relation":{},"ISSN":["1098-8823"],"issn-type":[{"value":"1098-8823","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sphingolipid metabolism as a marker of hepatotoxicity in drug-induced liver injury","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins & Other Lipid Mediators","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prostaglandins.2020.106484","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106484"}}